• Current trends in poor responder management
  R. Fanchin (France)
• The use of long-acting recombinant follicle-stimulation hormone for controlled ovarian stimulation
  N. Macklon (The Netherlands) 
• Factors predicting success in ovarian stimulation
  E. Bosch (Spain)
• Modified natural cycle
  M. J. Pelinck (The Netherlands)

• Prediction models
  N. Macklon (The Netherlands)
• Mild stimulation in poor responders
  J. H. Check (USA)
• Debate: Mild stimulation
  J. Zhang (USA)
• Debate: Conventional stimulation
  R. Fanchin (France)

Non-invasive assessment of oocytes and embryos

• Metabolomics
  I. Sánchez (Spain)
• Assessment of oocyte and embryo viability using Metabolomic profiling
  D. Sakkas (USA)
• Respiration 
  N. Ramsing (Denmark)
• Imaging
  M. Montag (Germany)

Fertility preservation

• Fertility preservation in pre-pubertal males 
  H. Tournaye (Belgium)
• Vitrification: Oocytes
  A. Cobo (Spain)
• Vitrification of human zygotes and embryos
  S. Al-Hasani (Germany)
• Freezing/drying of stem cells
  A. Arav (Israel)

Genetics and reproduction

• Origin of human aneuploidies
  T. Hassold (USA)
• The egg and the environment
  P. Hunt (USA)
• Male meiosis
  F. Vidal (Spain)
• Chromosomally abnormal human embryos
  L. Wilton (Australia)
• Debate: Is PGS appropriate for embryo selection?
  PGS may be suitable for certain paitents to select embryos: J. Cohen (USA)
  PGS is not suitable for certain patients to select embryos: P. Devroey (Belgium)

Environmental challenges to reproductive health

• Smoking
  S. Soares (Portugal)
• Body weight
  J. Bellver (Spain)
• Alcohol, caffeine and psychological stress
  H. Klonoff-Cohen (USA)
• Pollutants, sedentarism, circadian rhythm
  E. Younglai (Canada)

New technologies that will impact clinical practice

• Endometrial stem cells: Clinical relevance
  C. Gargett (Australia)
• Generation of artificial gametes from stell cells
  C. Simon (Spain)
• Maintenance of genetic integrity in embryos and stem cells 
  J. McCarrey (USA)
• Customized human embryonic stem cell (hESC) lines 
  A. Krtolica (USA)

Polycystic ovarian syndrome

• Intrauterine events and the risk of developing PCOS
  L. Ibañez (Spain)
• Life style and health risks
  H. Escobar-Morreale (Spain)
• In-vitro maturation (IVM) in PCO patients
  S. Tan (Canada)
• Induction of ovulation in PCOS: is there are first line treatment?
  R. Legro (USA)

Poor prognosis patients and benign gynaecological diseases in ART

• The influence of intramural fibroids
  A. Pellicer (Spain)
• What should be done with endometriomas?
  A. Arici (USA)
• Natural options in aged patients and low responders 
  N. Laufer (Israel) 
• The role of oocyte vitrification in aged patients and low responders
  J. Crespo (Spain)

Luteal phase support

• The need of luteal phase support in ART
  K. Diedrich (Germany)
• Gonadotropin-releasing hormone (GnRH) agonist in IVF
  J. Tesarik (Spain)
• Gonadotropin-releasing hormone (GnRH) agonist in intrauterine insemination (IUI)
  J. G. Velasco (Spain)
• The use of corticosteroids and anabolic and androgenic steroids (AAS)
  P. Barri (Spain)